1
|
Chalinor H, Bodek S, Bojadzieva J, Farouque O, Hare D, Johns J, Kearney L, Lim H, Lin T, Mirzaee S, Ramchand J, Salmon L, Stutterd C, Teh A, Valente G, Wallis M. The Introduction and Development of a Genetic Counsellor-led Cardiac Genetics Service in a Metropolitan Hospital. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Healy NA, Parag Y, Wallis MG, Tanner J, Kilburn-Toppin F. Outcomes of male patients attending the symptomatic breast unit: adherence to local and national imaging guidelines and effectiveness of clinical examination and imaging in detecting male breast cancer. Clin Radiol 2021; 77:e64-e74. [PMID: 34716007 DOI: 10.1016/j.crad.2021.09.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Accepted: 09/21/2021] [Indexed: 11/15/2022]
Abstract
AIM To review outcomes of male patients attending the breast unit, evaluate effectiveness of imaging and examination in detecting breast cancer and review adherence to guidelines for male breast imaging. MATERIALS AND METHODS A retrospective review was undertaken of male patients attending Cambridge Breast Unit from 1 January 2015 to 31 December 2019. Patient electronic records and imaging were reviewed to establish demographics, clinical findings, imaging, biopsy, and pathology outcomes. RESULTS Of 1,362 male patients attending the breast unit, 1,028 (75%) had imaging performed. Biopsy was performed in 41 men (3%), with 14 cancers diagnosed (1%). Clinical examination showed 42.7% sensitivity, 99.6% specificity, 54.6% positive predictive value (PPV) and 99.4% negative predictive value (NPV) for detection of cancer. Mammogram demonstrated 84.6% sensitivity, 99.4% specificity, 69.8% PPV, and 99.8% NPV for detection of malignancy. Ultrasound demonstrated 78.6% sensitivity, 98.9% specificity, 73.3% PPV and 99.2% NPV for detection of cancer. Forty-one percent of patients <40 years and 51% < 50 years were imaged, who according to local and Royal College of Radiologists (RCR) guidelines did not require imaging based on age and clinical score. CONCLUSION Male patients account for a small proportion of referrals to the breast unit but generate significant workload. Imaging protocols, incorporating clinical score and age cut-off at 40 years remains robust for detecting malignancy. Clinician awareness of the imaging protocol, and close liaison with radiologists is essential to minimise additional radiology workload.
Collapse
Affiliation(s)
- N A Healy
- Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrookes' Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
| | - Y Parag
- Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrookes' Hospital, Hills Road, Cambridge, CB2 0QQ, UK
| | - M G Wallis
- Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrookes' Hospital, Hills Road, Cambridge, CB2 0QQ, UK; NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Trust, Cambridge, UK
| | - J Tanner
- Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrookes' Hospital, Hills Road, Cambridge, CB2 0QQ, UK
| | - F Kilburn-Toppin
- Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrookes' Hospital, Hills Road, Cambridge, CB2 0QQ, UK
| |
Collapse
|
3
|
Blanks RG, Wallis MG, Alison RJ, Given-Wilson RM. An analysis of screen-detected invasive cancers by grade in the English breast cancer screening programme: are we failing to detect sufficient small grade 3 cancers? Eur Radiol 2020; 31:2548-2558. [PMID: 32997179 PMCID: PMC7979656 DOI: 10.1007/s00330-020-07276-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Revised: 07/31/2020] [Accepted: 09/09/2020] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Randomised controlled trials have shown a reduction in breast cancer mortality from mammography screening and it is the detection of high-grade invasive cancers that is responsible for much of this effect. We determined the detection rates of invasive cancers by grade, size and type of screen and estimated relative sensitivities with emphasis on grade 3 detection. METHODS This observational study analysed data from over 11 million screening episodes (67,681 invasive cancers) from the English NHS breast screening programme over seven screening years 2009/2010 to 2015/2016 for women aged 45-70. RESULTS At prevalent (first) screens (which are unaffected by screening interval), the detection rate of small (< 15 mm) invasive cancers was 0.95 per 1000 for grade 1, but for grade 3 only 0.30 per 1000. The ratio of small (< 15 mm) to large (≥ 15 mm) cancers was 1.8:1 for grade 1 but reversed to 0.5:1 for grade 3. We estimated that the relative sensitivity for grade 3 invasive cancers was 52% of that for grade 1 and the relative sensitivity for small (< 15 mm) grade 3 only 26% of that for small (< 15 mm) grade 1 invasive cancers. CONCLUSIONS Sensitivity for small grade 3 invasive cancers is poor compared with that for grade 1 and 2 invasive cancers and larger grade 3 malignancies. This observation is likely a limitation of the current technology related to the absence of identifiable mammographic features for small high-grade cancers. Future work should focus on technologies and strategies to improve detection of these clinically most significant cancers. KEY POINTS • The detection of small high-grade invasive cancers is vital to reduce breast cancer mortality. • We estimate the sensitivity for small grade 3 invasive cancers may be only 26% of that of small grade 1 invasive cancers. This is likely to be associated with the non-specific mammographic features for these cancers. • New technologies and appropriate strategies using current technology are required to maximise the detection of small grade 3 invasive cancers.
Collapse
Affiliation(s)
- R G Blanks
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF, UK.
| | - M G Wallis
- MBCHB Cambridge Breast Unit, and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Trust, Cambridge, UK
| | - R J Alison
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF, UK
| | - R M Given-Wilson
- Department of Radiology, St Georges University Hospital Foundation Trust, London, UK
| |
Collapse
|
4
|
Morgan J, Potter S, Sharma N, McIntosh SA, Coles CE, Dodwell D, Elder K, Gaunt C, Lyburn ID, McIntosh SA, Morgan J, Paramasivan S, Pinder S, Pirrie S, Potter S, Rea D, Roberts T, Sharma N, Stobart H, Taylor-Phillips S, Wallis M, Wilcox M. The SMALL Trial: A Big Change for Small Breast Cancers. Clin Oncol (R Coll Radiol) 2019; 31:659-663. [PMID: 31160130 DOI: 10.1016/j.clon.2019.05.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 04/16/2019] [Accepted: 05/13/2019] [Indexed: 11/16/2022]
Affiliation(s)
- J Morgan
- University of Sheffield, FU32, The Medical School, Sheffield, UK
| | - S Potter
- Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, Bristol, UK; Bristol Breast Care Centre, Southmead Hospital, Bristol, UK
| | - N Sharma
- Breast Unit, St James Hospital, Leeds, UK
| | - S A McIntosh
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.
| | | | | | - K Elder
- Western General Hospital, Edinburgh, UK
| | - C Gaunt
- CRCTU, University of Birmingham, UK
| | | | | | | | | | | | - S Pirrie
- CRCTU, University of Birmingham, UK
| | | | - D Rea
- University of Birmingham, UK
| | | | - N Sharma
- St James's University Hospital, Leeds, UK
| | - H Stobart
- Independent Cancer Patients' Voice, UK
| | | | - M Wallis
- Addenbrooke's Hospital, Cambridge, UK
| | - M Wilcox
- Independent Cancer Patients' Voice, UK
| |
Collapse
|
5
|
Blanks RG, Given-Wilson RM, Cohen SL, Patnick J, Alison RJ, Wallis MG. Correction to: An analysis of 11.3 million screening tests examining the association between recall and cancer detection rates in the English NHS breast cancer screening programme. Eur Radiol 2019; 29:7074-7075. [PMID: 31278572 DOI: 10.1007/s00330-019-06307-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The original version of this article, published on 04 February 2019, unfortunately contained a mistake.
Collapse
Affiliation(s)
- R G Blanks
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Oxford, UK.
| | - R M Given-Wilson
- Department of Radiology, St Georges University Hospital Foundation Trust, London, UK
| | | | - J Patnick
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Oxford, UK
| | - R J Alison
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Oxford, UK
| | - M G Wallis
- Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Trust, Cambridge, UK
| |
Collapse
|
6
|
Blanks RG, Given-Wilson RM, Cohen SL, Patnick J, Alison RJ, Wallis MG. An analysis of 11.3 million screening tests examining the association between recall and cancer detection rates in the English NHS breast cancer screening programme. Eur Radiol 2019; 29:3812-3819. [PMID: 30715589 DOI: 10.1007/s00330-018-5957-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Revised: 11/12/2018] [Accepted: 12/05/2018] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To develop methods to model the relationship between cancer detection and recall rates to inform professional standards. METHODS Annual screening programme information for each of the 80 English NHSBSP units (totalling 11.3 million screening tests) for the seven screening years from 1 April 2009 to 31 March 2016 and some Dutch screening programme information were used to produce linear and non-linear models. The non-linear models estimated the modelled maximum values (MMV) for cancers detected at different grades and estimated how rapidly the MMV was reached (the modelled 'slope' (MS)). Main outcomes include the detection rate for combined invasive/micro-invasive and high-grade DCIS (IHG) detection rate and the low/intermediate grade DCIS (LIG) detection rate. RESULTS At prevalent screens for IHG cancers, 99% of the MMV was reached at a recall rate of 7.0%. The LIG detection rate had no discernible plateau, increasing linearly at a rate of 0.12 per 1000 for every 1% increase in recall rate. At incident screens, 99% of the MMV for IHG cancer detection was 4.0%. LIG DCIS increased linearly at a rate of 0.18 per 1000 per 1% increase in recall rate. CONCLUSIONS Our models demonstrate the diminishing returns associated with increasing recall rates. The screening programme in England could use the models to set recall rate ranges, and other countries could explore similar methodology. KEY POINTS • Question: How can we determine optimum recall rates in breast cancer screening? • Findings: In this large observational study, we show that increases in recall rates above defined levels are almost exclusively associated with false positive recalls and a very small increase in low/intermediate grade DCIS. • Meaning: High recall rates are not associated with increases in detection of life-threatening cancers. The models developed in this paper can be used to help set recall rate ranges that maximise benefit and minimise harm.
Collapse
Affiliation(s)
- R G Blanks
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Oxford, UK.
| | - R M Given-Wilson
- Department of Radiology, St Georges University Hospital Foundation Trust, London, UK
| | | | - J Patnick
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Oxford, UK
| | - R J Alison
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Oxford, UK
| | - M G Wallis
- Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Trust, Cambridge, UK
| |
Collapse
|
7
|
Blanks RG, Given-Wilson R, Alison R, Jenkins J, Wallis MG. An analysis of 11.3 million screening tests examining the association between needle biopsy rates and cancer detection rates in the English NHS Breast Cancer Screening Programme. Clin Radiol 2019; 74:384-389. [PMID: 30799096 DOI: 10.1016/j.crad.2019.01.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Accepted: 01/23/2019] [Indexed: 11/24/2022]
Abstract
AIM To examine the association between recall, needle biopsy, and cancer detection rates to inform the setting of target ranges to optimise the benefit to harm ratio of breast screening programmes. MATERIALS AND METHODS Annual screening programme information from 2009/10 to 2015/16 for the 80 screening units of the English National Health Service Breast Screening Programme (totalling 11.3 million screening tests) was obtained from annual (KC62) returns. Linear regression models were used to examine the association between needle biopsy rates and recall rates and non-linear regression models to examine the association between cancer detection rates and needle biopsy rates. RESULTS The models show and quantify the diminishing returns for prevalent screens with increasing biopsy rates. A biopsy rate increase from 10 to 20 per 1,000 increases the cancer detection rate by 2.13 per 1,000 with four extra biopsies per extra cancer detected. Increasing the biopsy rate from 40 to 50 per 1,000, increases the cancer detection rate by only 0.25 per 1,000, with 40 extra biopsies per extra cancer detected. Although diminishing returns are also seen at incident screens, screening is generally more efficient. CONCLUSIONS Increasing needle biopsy rates leads to rapidly diminishing returns in cancer detection and a marked increase in non-malignant/benign needle biopsies. Much of the harms associated with screening in terms of false-positive recall rates and non-cancer biopsies occur at prevalent screens with much lower rates at incident screens. Needle biopsy rate targets should be considered together with recall rate targets to maximise benefit and minimise harm.
Collapse
Affiliation(s)
- R G Blanks
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF, UK.
| | - R Given-Wilson
- Department of Radiology, St Georges University Hospital Foundation Trust, UK
| | - R Alison
- Cancer Epidemiology Unit, Nuffield Department of Population Health, Oxford University, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF, UK
| | - J Jenkins
- Breast Screening Programme, Public Health England, London, UK
| | - M G Wallis
- Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Trust, UK
| |
Collapse
|
8
|
Wallis M, Akhtar F, Azam M. Emergency Admissions of Children and Young People with Mental Health Needs to the Paediatric Ward. Ir Med J 2018; 111:795. [PMID: 30520288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- M Wallis
- Department of Paediatrics, Wexford General Hospital, Ireland
| | - F Akhtar
- Department of Paediatrics, Wexford General Hospital, Ireland
| | - M Azam
- Department of Paediatrics, Wexford General Hospital, Ireland
| |
Collapse
|
9
|
Fallowfield LJ, Matthews L, Jenkins VA, May SF, Francis A, Rae D, Wallis M. Abstract OT3-08-01: Interview data from women contemplating LORIS trial entry during the feasibility study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: LORIS is a multi-centre, randomised (1:1) controlled trial of Surgery v Active Monitoring with annual mammography in patients with low risk ductal carcinoma in situ (DCIS). During a 2 year Feasibility Study potential patients were invited to complete the Clinical Trials Questionnaire (CTQ)1 and participate in a semi structured telephone interview about the verbal, written and DVD based trial information. The DVD was produced to complement the patient information sheet (PIS) and incorporates simple graphics and a Q&A session with women asking the Chief Investigator questions about the trial.
Aims:To examine the reasons for trial participation/rejection and obtain feedback about the clarity, timing and usefulness of the PIS and DVD in order to identify potential communication drivers and barriers to trial recruitment.
Methods: Participants completed the CTQ1 prior to randomisation and with their consent were contacted following randomisation for an interview. Women declining the trial were issued with an optional pack containing the CTQ1 and the researchers' contact details if they wanted an interview. The CTQ1 comprises16 reasons that might influence a decision to either accept or decline a trial. For each statement participants register their agreement or disagreement on a scale of 1 (strongly agree) to 5 (strongly disagree) and indicate the most important reason for their decision. Interviews explored factors such as, attitudes about randomisation, and usefulness of the trial information provided.
Results: 41 patients were randomised during feasibility; 20 surgery, 21 active monitoring, 16 patients declined the trial. 40/41(98%) acceptors and 9/16 (56%) decliners completed the CTQ1. The main reason for joining LORIS was:- “I thought the trial offered the best treatment available” 13/40 (32%) and for decling the trial was “The idea of randomisation worried me” (4/9; 44%).
35 interviews were conducted (31/41 (76%) accepted and 4/16 (25%) declined LORIS). At interview acceptors commented that the PIS was very useful and clear (84%; 26/31 & 90%; 28/31, respectively). 74% (23/31) of women who joined LORIS watched the DVD and the majority (19/23; 83%) found it “very useful” and 22 (22/23; 96%) “very easy to understand”. A third of women (10/31) said the PIS and the DVD helped them decide to participate in LORIS. Women who declined the trial had clear treatment preferences; 2/4 did not watch the DVD. Three quarters of women interviewed (19/25) watched the DVD with family members/friends and found it reassuring. One commented it was “Put in words you can understand and not be baffled by”. The most popular aspect was the Q&A session (13/25; 52%).
Conclusions:The LORIS DVD was a useful, easy to understand recruitment tool, complementing the PIS. Many women felt reassured that the content was consistent with, and added to that provided by healthcare professionals. Opinions of family and friends, worries about randomisation and personal preferences exert an influence of those declining these types of trial.
Fallowfield LJ, Jenkins V, et al. (1998) Attitudes of patients to randomised clinical trials of cancer therapy. Eur J Cancer 34(10):1554–1559.
Citation Format: Fallowfield LJ, Matthews L, Jenkins VA, May SF, Francis A, Rae D, Wallis M. Interview data from women contemplating LORIS trial entry during the feasibility study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-08-01.
Collapse
Affiliation(s)
- LJ Fallowfield
- SHORE-C, BSMS, University of Sussex, Brighton, East Sussex, United Kingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Addenbrook's Hospital, Cambridge, United Kingdom
| | - L Matthews
- SHORE-C, BSMS, University of Sussex, Brighton, East Sussex, United Kingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Addenbrook's Hospital, Cambridge, United Kingdom
| | - VA Jenkins
- SHORE-C, BSMS, University of Sussex, Brighton, East Sussex, United Kingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Addenbrook's Hospital, Cambridge, United Kingdom
| | - SF May
- SHORE-C, BSMS, University of Sussex, Brighton, East Sussex, United Kingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Addenbrook's Hospital, Cambridge, United Kingdom
| | - A Francis
- SHORE-C, BSMS, University of Sussex, Brighton, East Sussex, United Kingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Addenbrook's Hospital, Cambridge, United Kingdom
| | - D Rae
- SHORE-C, BSMS, University of Sussex, Brighton, East Sussex, United Kingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Addenbrook's Hospital, Cambridge, United Kingdom
| | - M Wallis
- SHORE-C, BSMS, University of Sussex, Brighton, East Sussex, United Kingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Addenbrook's Hospital, Cambridge, United Kingdom
| |
Collapse
|
10
|
Cox KL, Sharma N, Taylor-Phillips S, Weeks J, Mills P, Lim A, Haigh I, Sever A, Wallis M, DeSilva T, Hashem M. Abstract PD2-04: Enhanced pre-operative axillary staging using intradermal microbubbles and contrast-enhanced ultrasound (CEUS) to identify and biopsy sentinel lymph nodes (SLN) in breast cancer is a reproducible technique and may characterise a group of patients who can completely avoid axillary surgery. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd2-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose
In patients with breast cancer, avoiding overtreatment of the axilla without compromising oncological outcomes is an important clinical goal. Previous work has suggested that patients with a normal grey-scale ultrasound and benign radiological core biopsy of SLN identified with CEUS are unlikely to have high volume axillary metastases. We therefore assessed the reproducibility of this biopsy technique in multiple centres and in 2 centres, measured the volume of axillary metastases at the end of primary surgical treatment in patients with a false negative SLN core biopsy.
Materials and Methods
Between 2010 and 2016 data were collected on patients with early breast cancer; 1361 from Maidstone Breast Clinic (1) (prospective, sequential), 376 from Tunbridge Wells Breast Clinic (2) (retrospective, sequential), 122 from Leeds Breast Clinic (3) (retrospective, selected) and 48 from Imperial College Healthcare (4) (prospective, selected). Patients at Centres 1 and 2 had a normal grey-scale axillary ultrasound. Patients had a CEUS SLN core biopsy procedure prior to axillary surgery (sentinel lymph node excision (SLNE)/axillary lymph node dissection (ALND)).
Results
SLN were successfully core biopsied (nodal tissue retrieved) in 80% (Centre 1), 79.5% (Centre 2), 77.5% (Centre 3) and 88% (Centre 4). Patients with invasive breast cancer and a successful SLN core biopsy went on to have primary surgical treatment, 816 (Centre 1), 215 (Centre 2), 80 (Centre 3) and 38 (Centre 4). As a test to identify all SLN metastases, the sensitivities were 47.5% (95% CI 39.9-55.1), 52.5% (95% CI 39.1-65.7), 46.4% (95% CI 27.5-66.1) and 45.5% (95% CI 16.7-76.6) respectively. Specificities; 99.7% (95% CI 98.9-100), 98.1 (95% CI 94.5-99.6), 100% (95% CI 93.2-100%) and 96.3% (95% CI 81-99.9) respectively. Negative predictive values; 87.3% (95% CI 84.6-89.6), 84.5% (95% CI 78.4-89.5), 86.9% (95% CI 82.4-90.3) and 86.2% (95% CI 78.4-91.5) respectively. At Centres 1 and 2, 13/637 (2%) and 6/183 (3%) respectively of patients with a benign microbubble/ CEUS SLN core biopsy had 2 or more LN macrometastases found at SLNE/ ALND.
Conclusion
The identification and biopsy of SLN using CEUS is a reproducible technique. Despite the low sensitivity, the negative predictive value is high and in a large cohort of patients from centres 1 and 2, only a small proportion of patients had 2 or more 2 lymph node macro metastases that were both occult on grey-scale ultrasound and missed by SLN core biopsy. In the era of axillary conservation, these results indicate that some patients may be suitable for complete radiological staging of the axilla and thus safely avoid axillary surgery.
Citation Format: Cox KL, Sharma N, Taylor-Phillips S, Weeks J, Mills P, Lim A, Haigh I, Sever A, Wallis M, DeSilva T, Hashem M. Enhanced pre-operative axillary staging using intradermal microbubbles and contrast-enhanced ultrasound (CEUS) to identify and biopsy sentinel lymph nodes (SLN) in breast cancer is a reproducible technique and may characterise a group of patients who can completely avoid axillary surgery [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD2-04.
Collapse
Affiliation(s)
- KL Cox
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - N Sharma
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - S Taylor-Phillips
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - J Weeks
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - P Mills
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - A Lim
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - I Haigh
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - A Sever
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - M Wallis
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - T DeSilva
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| | - M Hashem
- Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; WMS - Population Evidence and Technologies, University of Warwick, Coventry, United Kingdom; Leeds Breast Unit, Leeds, Yorkshire, United Kingdom; Breast Care Unit, Kings College Hospital, London, United Kingdom; Charing Cross Hospital, London, United Kingdom; Addenbrooke's Treatment Centre, Cambridge, United Kingdom; School of Surgery, KSS, London, United Kingdom
| |
Collapse
|
11
|
Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, Kearins O, Ball GR, Tomlinson I, Hanby AM, Thomas J, Maxwell AJ, Wallis MG, Dodwell DJ. Abstract P4-15-02: Impact of radiotherapy and endocrine therapy on further events: Final multivariate analysis of a prospective, national cohort study of screen detected ductal carcinoma in situ (DCIS) of the breast. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Key words: DCIS, radiotherapy, endocrine therapy, survival, surgical margins
Background:
The benefits and risks of breast screening remain controversial, with particular concern that ductal carcinoma in situ (DCIS) may be over-diagnosed and over-treated. There is little prospective data on treatment or outcomes for screen detected DCIS.
Methods:
A prospective cohort of non-invasive lesions diagnosed through the United Kingdom National Health Service Breast Screening Programme (NHSBSP) (1 April 2003 to 31 March 2012) was linked to national databases and case note review to analyse patterns of care, recurrence and mortality.
Results:
Screen-detected DCIS in 9938 women was analysed, 33% (9938/30041) of women with a final diagnosis of non-invasive breast neoplasia diagnosed through the NHSBSP over the same time.
The patients (mean age was 60 years: range 46-87 years) were treated by breast conservation surgery (BCS; 7007; 70.5%) or mastectomy (2931). At 64 months median follow up, 697 (6.8%) had further DCIS or invasive breast cancer after BCS (7.8%) or mastectomy (4.5%) (p<0.001) and 228 women (2.3%) developed contralateral malignancy.
Breast radiotherapy (RT) after BCS (4363/7007; 62%) was associated with a 3.1% absolute reduction in any ipsilateral DCIS or invasive cancer (No RT: 7.2% vs RT: 4.1% (p<0.001) and a 1.9% absolute reduction for ipsilateral invasive breast recurrence (No RT: 3.8% vs RT: 1.9% (p<0.001), independent of excision margin width or size of DCIS. Women who did not receive RT after BCS had more ipsilateral events (p=0.008) when the radial excision margin was <2mm. RT was rarely used after mastectomy for DCIS (33 women). Adjuvant endocrine therapy (prescribed for 1208/9938; 12.2%) was associated with a reduction in any ipsilateral recurrence, independent of whether women did (HR 0.57: 95% CI 0.41 - 0.80) or did not (HR 0.68: 95% CI 0.51 - 0.91) receive RT after BCS.
Among 321 (3.2%) women who died, 46 deaths (0.5%; 14.3% of all deaths) were attributed to invasive breast cancer. Death from breast cancer was uncommon and outnumbered 5:1 by death due to other causes. RT after BCS was associated with a non-significant 0.2% absolute reduction in breast cancer mortality. However, women who developed invasive breast cancer had a worse survival than those with further DCIS (p<0.001).
Conclusions:
Recurrent DCIS or invasive cancer is uncommon following screen detected DCIS treated by surgery and adjuvant therapy. Both RT and endocrine therapy following surgery were associated with a significant reduction in further DCIS and invasive disease, but not breast cancer mortality, within 5 years of diagnosis. This study quantifies the benefits of radiotherapy and endocrine therapy to inform decision making in the management of screen detected DCIS.
Citation Format: Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, Kearins O, Ball GR, Tomlinson I, Hanby AM, Thomas J, Maxwell AJ, Wallis MG, Dodwell DJ. Impact of radiotherapy and endocrine therapy on further events: Final multivariate analysis of a prospective, national cohort study of screen detected ductal carcinoma in situ (DCIS) of the breast [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-15-02.
Collapse
Affiliation(s)
- AM Thompson
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - K Clements
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - S Cheung
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - SE Pinder
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - G Lawrence
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - E Sawyer
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - O Kearins
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - GR Ball
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - I Tomlinson
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - AM Hanby
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - J Thomas
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - AJ Maxwell
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - MG Wallis
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| | - DJ Dodwell
- The University of Texas MD Anderson Cancer Center, Houston, TX; Public Health England; Guy's Hospital; Nottingham Trent University, Nottingham, United Kingdom; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford, United Kingdom; St James Hospital, Leeds, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals, Cambridge, United Kingdom; University of Oxford, Oxford, United Kingdom
| |
Collapse
|
12
|
Ramchand J, Wallis M, Farouque O, Trainer A, Macciocca I, Lynch E, Martyn M, Phelan D, Chong B, Zentner D, Vohra J, James P, Hare D. A Prospective Evaluation of Whole-Exome Sequencing in Idiopathic Dilated Cardiomyopathy and Related Phenotypes. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Warren LM, Halling-Brown MD, Looney PT, Dance DR, Wallis MG, Given-Wilson RM, Wilkinson L, McAvinchey R, Young KC. Image processing can cause some malignant soft-tissue lesions to be missed in digital mammography images. Clin Radiol 2017; 72:799.e1-799.e8. [PMID: 28457521 DOI: 10.1016/j.crad.2017.03.024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 01/24/2017] [Accepted: 03/23/2017] [Indexed: 11/19/2022]
Abstract
AIM To investigate the effect of image processing on cancer detection in mammography. METHODS AND MATERIALS An observer study was performed using 349 digital mammography images of women with normal breasts, calcification clusters, or soft-tissue lesions including 191 subtle cancers. Images underwent two types of processing: FlavourA (standard) and FlavourB (added enhancement). Six observers located features in the breast they suspected to be cancerous (4,188 observations). Data were analysed using jackknife alternative free-response receiver operating characteristic (JAFROC) analysis. Characteristics of the cancers detected with each image processing type were investigated. RESULTS For calcifications, the JAFROC figure of merit (FOM) was equal to 0.86 for both types of image processing. For soft-tissue lesions, the JAFROC FOM were better for FlavourA (0.81) than FlavourB (0.78); this difference was significant (p=0.001). Using FlavourA a greater number of cancers of all grades and sizes were detected than with FlavourB. FlavourA improved soft-tissue lesion detection in denser breasts (p=0.04 when volumetric density was over 7.5%) CONCLUSIONS: The detection of malignant soft-tissue lesions (which were primarily invasive) was significantly better with FlavourA than FlavourB image processing. This is despite FlavourB having a higher contrast appearance often preferred by radiologists. It is important that clinical choice of image processing is based on objective measures.
Collapse
Affiliation(s)
- L M Warren
- National Co-ordinating Centre for the Physics of Mammography, Royal Surrey County Hospital NHS Foundation Trust, Guildford, GU2 7XX, UK.
| | - M D Halling-Brown
- Scientific Computing, Royal Surrey County Hospital NHS Foundation Trust, Guildford, GU2 7XX, UK
| | - P T Looney
- National Co-ordinating Centre for the Physics of Mammography, Royal Surrey County Hospital NHS Foundation Trust, Guildford, GU2 7XX, UK
| | - D R Dance
- National Co-ordinating Centre for the Physics of Mammography, Royal Surrey County Hospital NHS Foundation Trust, Guildford, GU2 7XX, UK; Department of Physics, University of Surrey, Guildford, Surrey, GU2 7JP, UK
| | - M G Wallis
- Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, CB2 0QQ, UK
| | - R M Given-Wilson
- Department of Radiology, St George's University Hospitals NHS Foundation Trust, Tooting, London, SW17 0QT, UK
| | - L Wilkinson
- Department of Radiology, St George's University Hospitals NHS Foundation Trust, Tooting, London, SW17 0QT, UK
| | - R McAvinchey
- Jarvis Breast Screening and Diagnostic Centre, Guildford, GU1 1LJ, UK
| | - K C Young
- National Co-ordinating Centre for the Physics of Mammography, Royal Surrey County Hospital NHS Foundation Trust, Guildford, GU2 7XX, UK; Department of Physics, University of Surrey, Guildford, Surrey, GU2 7JP, UK
| |
Collapse
|
14
|
Francis A, Bartlett J, Billingham L, Bowden S, Brookes C, Dodwell D, Evans A, Fairbrother P, Fallowfield L, Gaunt C, Hanby A, Jenkins V, Matthews L, Pinder S, Pirrie S, Rea D, Reed M, Roberts T, Thomas J, Wallis M, Wilcox M, Young J. Abstract OT1-03-01: The UK LORIS trial: Randomizing patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot1-03-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The independent review of the UK National Health Service Breast Screening Programme reported (The Lancet, Volume 380, Issue 9855, Page 1778, 17 Nov 2012) on the benefits and harms of breast screening. It concluded that breast screening saves lives and acknowledged the existence of overtreatment. It encouraged randomized trials to elucidate the appropriate treatment of screen-detected DCIS to gain a better understanding of its natural history. The LORIS trial addresses the possible overtreatment of low and low/intermediate grade screen-detected (low risk) DCIS by randomizing patients to standard surgical treatment or active monitoring, each with long term follow up.
Trial Design: LORIS is a phase III, multicentre, 2 arm study, with a built in 2 year Feasibility Phase, in patients confirmed to have low risk DCIS defined by strict criteria and determined by central pathology review. Patients will be randomized between standard surgery and active monitoring with annual mammography. Patients will be followed up for a minimum of 10 years.
Eligibility Criteria:
1) Female, age ≥ 46 years
2) Screen-detected or incidental microcalcification (with no mass lesion clinically or on imaging)
3) Low risk DCIS on large volume vacuum-assisted biopsy, confirmed by central pathology review
4) Patient fit to undergo surgery
5) No previous breast cancer or ipsilateral DCIS diagnosis
6) Written informed consent
Specific Aims: The LORIS Trial aims to establish whether patients with newly diagnosed low risk DCIS can safely avoid surgery without detriment to their wellbeing (psychological and physical) and whether those patients that do require surgery can be identified by pathological and radiological means.
Primary endpoint: Ipsilateral invasive breast cancer free survival time
Secondary endpoints: Overall survival; mastectomy rate; time to mastectomy; time to surgery; patient reported outcomes; health resource utilisation and assessment of predictive biomarkers.
A digital image data repository and tissue bank will provide a prospective resource for both translational and imaging studies.
Statistical Methods: A total of 932 patients will be randomized to a non-inferiority design to test the null hypothesis that active monitoring of women diagnosed with low risk DCIS is not non-inferior in terms of ipsilateral invasive breast cancer free survival (iiBCFS) time compared to treatment with surgery. The iiBCFS time will be compared across the two arms on a per protocol and intent-to-treat basis, using a 1-sided (α=0.05) log-rank test for non-inferiority. The iiBCFS rate is assumed to be 97.5% in the surgery arm at 5 years, utilizing 80% power to exclude a difference of more than 2.5% in the active monitoring arm.
Present Accrual and Target Accrual: 32 UK centres are open for the Feasibility Phase of the trial which is nearing completion. The web-based central pathology review process is functioning efficiently, with a one week maximum turn around. Registrations and sites randomizing patients are on or above target. Randomizations are currently approximately 70% of target. A total of 60 centres will open in the main trial.
Contact Information: For further information, please email the LORIS Trial Office LORIS@trials.bham.ac.uk.
Citation Format: Francis A, Bartlett J, Billingham L, Bowden S, Brookes C, Dodwell D, Evans A, Fairbrother P, Fallowfield L, Gaunt C, Hanby A, Jenkins V, Matthews L, Pinder S, Pirrie S, Rea D, Reed M, Roberts T, Thomas J, Wallis M, Wilcox M, Young J. The UK LORIS trial: Randomizing patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-03-01.
Collapse
Affiliation(s)
- A Francis
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - J Bartlett
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - L Billingham
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - S Bowden
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - C Brookes
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - D Dodwell
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - A Evans
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - P Fairbrother
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - L Fallowfield
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - C Gaunt
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - A Hanby
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - V Jenkins
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - L Matthews
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - S Pinder
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - S Pirrie
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - D Rea
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - M Reed
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - T Roberts
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - J Thomas
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - M Wallis
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - M Wilcox
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| | - J Young
- University Hospital Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom; University of Leicester, Leicester, United Kingdom; St James's Hospital, Leeds, United Kingdom; University of Dundee, Dundee, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; SHORE-C, Brighton and Sussex Medical School, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; Brighton and Sussex Medical School, Brighton, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom
| |
Collapse
|
15
|
Blanks RG, Moss SM, Wallis MG. Monitoring and evaluating the UK National Health Service Breast Screening Programme: evaluating the variation in radiological performance between individual programmes using PPV-referral diagrams. J Med Screen 2016; 8:24-8. [PMID: 11373846 DOI: 10.1136/jms.8.1.24] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
A high quality breast cancer screening programme can be defined as one offering both a high cancer detection rate and a low referral rate of women for further investigation. Such a programme will have as few women as possible undergoing further investigations who do not have a final diagnosis of breast cancer—that is, a high positive predictive value of referral for further investigation. This paper introduces a graphical technique to illustrate individual programme performance. The graph plots positive predictive value of referral against referral rate, with the cancer detection rate expressed as “isobars” on the graph. Confidence limits can be expressed as “boxes” on the diagram. The graph not only illustrates programme performance but also enables suggestions to be made to improve performance. The definition of high quality screening is seen to have a subjective element as well as an objective element, as radiologists have to balance screening sensitivity with specificity. The technique is illustrated using data from the individual screening programmes in the UK National Health Service Breast Screening Programme for the screening year 1 April 1998 to 31 March 1999. The methodology could also be applied to other national screening programmes.
Collapse
Affiliation(s)
- R G Blanks
- Cancer Screening Evaluation Unit, Institute of Cancer Research, Section of Epidemiology, D Block, Cotswold Road, Sutton, Surrey SM2 5QF, UK.
| | | | | |
Collapse
|
16
|
Chaboyer W, Bucknall T, McInnes E, Wallis M. ISQUA16-2368THE EFFECT OF A PATIENT CENTRED CARE BUNDLE INTERVENTION ON PRESSURE ULCER INCIDENCES (INTACT). Int J Qual Health Care 2016. [DOI: 10.1093/intqhc/mzw104.30] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Francis A, Fallowfield L, Bartlett J, Thomas J, Wallis M, Hanby A, Pinder S, Evans A, Billingham L, Brookes C, Dodwell D, Fairbrother P, Gaunt C, Jenkins V, Matthews L, Pirrie S, Reed M, Roberts T, Wilcox M, Young J, Rea D. Abstract OT2-02-04: The LORIS trial: A multicentre, randomised phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot2-02-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The independent review of the UK National Health Service Breast Screening Programme reported (The Lancet, Volume 380, Issue 9855, Pages 1778 - 1786, 17 November 2012) on the benefits & harms of breast screening. It concluded that breast screening saves lives & acknowledged overtreatment. It encouraged randomized trials to elucidate the appropriate treatment of screen-detected ductal carcinoma in situ (DCIS) to gain a better understanding of its natural history. The LORIS trial addresses overtreatment of low & low/Intermediate grade screen detected (low risk) DCIS by randomizing patients to standard surgical treatment or active monitoring.
Trial Design: LORIS is a phase III, multicentre, 2 arm study, with a 2 year feasibility phase, in patients confirmed to have low risk DCIS by central pathology review. Patients are randomised to standard surgery or active monitoring with annual mammography. Patients will be followed up for a minimum of 10 years.
Key Eligibility Criteria:
1) Female 46 years or over.
2) Screen-detected or incidental microcalcification (with no mass lesion clinically or on imaging)
3) Low risk DCIS on large volume vacuum-assisted biopsy, confirmed by central pathology review
4) Patient fit to undergo surgery
Specific Aims: The LORIS Trial aims to establish whether patients with newly diagnosed low risk DCIS can safely avoid surgery without detriment to their wellbeing (psychological and physical) & whether those patients that do require surgery can be identified by pathological and radiological means.
Primary endpoint: Ipsilateral invasive breast cancer free survival rate at 5 years
Secondary endpoints: Overall survival; mastectomy rate; time to mastectomy; time to surgery; patient reported outcomes & health resource utilisation.
A digital image data repository and tissue bank provide a prospective resource for both translational & imaging studies.
Statistical Methods: A total of 932 patients will be randomized to a non-inferiority design to test the null hypothesis that active monitoring of women diagnosed with low risk DCIS is not non-inferior in terms of 5 year ipsilateral invasive breast cancer free survival (iiBCFS) rate compared to treatment with surgery. The iiBCFS rate will be compared across the two arms on a per protocol and intent-to-treat basis, using a 1-sided (α=0.05) log-rank test for non-inferiority. The iiBCFS rate is assumed to be 97.5% in the surgery arm giving 80% power to exclude a difference of more than 2.5% in the active monitoring arm at 5 years.
Present Accrual and Target Accrual: 21 UK centres are open & the feasibility phase of the trial is recruiting to target. The web based central pathology review process is functioning well with a one week maximum turn around. A further 40 centres will be opened on completion of the feasibility phase.
Contact: LORIS@trials.bham.ac.uk
This project was funded by the National Institute for Health Research [Health Technology Assessment Programme] (project number 11/36/16)
Department of Health Disclaimer: The views & opinions expressed therein are those of the authors & do not necessarily reflect those of the Health Technology Assessment Programme, NIHR, NHS or the Department of Health.
Citation Format: Francis A, Fallowfield L, Bartlett J, Thomas J, Wallis M, Hanby A, Pinder S, Evans A, Billingham L, Brookes C, Dodwell D, Fairbrother P, Gaunt C, Jenkins V, Matthews L, Pirrie S, Reed M, Roberts T, Wilcox M, Young J, Rea D. The LORIS trial: A multicentre, randomised phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT2-02-04.
Collapse
Affiliation(s)
- A Francis
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - L Fallowfield
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - J Bartlett
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - J Thomas
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - M Wallis
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - A Hanby
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - S Pinder
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - A Evans
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - L Billingham
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - C Brookes
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - D Dodwell
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - P Fairbrother
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - C Gaunt
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - V Jenkins
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - L Matthews
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - S Pirrie
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - M Reed
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - T Roberts
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - M Wilcox
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - J Young
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| | - D Rea
- University Hospital Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom; Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; Western General Hospital, Edinburgh, Scotland, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Leeds, Leeds, Yorkshire, United Kingdom; King's College London, London, United Kingdom; Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; University of Birmingham, Birmingham, West Midlands, United Kingdom; ICPV, London, United Kingdom; Brighton & Sussex Medical School, Brighton, Sussex, United Kingdom
| |
Collapse
|
18
|
Evans DG, Thomas S, Caunt J, Roberts L, Howell A, Wilson M, Fox R, Sibbering DM, Moss S, Wallis MG, Eccles DM, Duffy S. Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02). Fam Cancer 2015; 13:13-21. [PMID: 23733252 DOI: 10.1007/s10689-013-9661-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Although there have been encouraging recent studies showing a potential benefit from annual mammography in women aged 40-49 years of age with an elevated breast cancer risk due to family history there is little evidence of efficacy in women aged <40 years of age. A prospective study (FH02) has been developed to assess the efficacy of mammography screening in women aged 35-39 years of age with a lifetime breast cancer risk of ≥ 17 % who are not receiving MRI screening. Retrospective analyses from five centres with robust recall systems identified 47 breast cancers (n = 12 in situ) with an interval cancer rate of 15/47 (32%). Invasive tumour size, lymph node status and current vital status were all significantly better than in two control groups of unscreened women (including those with a family history) recruited to the POSH study. Further evaluation of the prospective arm of FH02 is required to assess the potential added value of digital mammography and the cancer incidence rates in moderate and high risk women in order to inform cost effectiveness analyses.
Collapse
Affiliation(s)
- D G Evans
- Genesis Breast Cancer Prevention Centre, University Hospital of South Manchester NHS Trust, Wythenshawe, Manchester, M23 9LT, UK,
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Drew M, Wallis M, Hughes D. The AIS consensus statement on the definition of injury and illness. J Sci Med Sport 2014. [DOI: 10.1016/j.jsams.2014.11.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Crilly J, O'Dwyer J, Lind J, Tippett V, Thalib L, O'Dwyer M, Keijzers G, Wallis M, Bost N, Shiels S. Impact of opening a new emergency department on healthcare service and patient outcomes: analyses based on linking ambulance, emergency and hospital databases. Intern Med J 2014; 43:1293-303. [PMID: 23734944 DOI: 10.1111/imj.12202] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2012] [Accepted: 05/22/2013] [Indexed: 11/30/2022]
Abstract
BACKGROUND Emergency department (ED) crowding caused by access block is an increasing public health issue and has been associated with impaired healthcare delivery, negative patient outcomes and increased staff workload. AIM To investigate the impact of opening a new ED on patient and healthcare service outcomes. METHODS A 24-month time series analysis was employed using deterministically linked data from the ambulance service and three ED and hospital admission databases in Queensland, Australia. RESULTS Total volume of ED presentations increased 18%, while local population growth increased by 3%. Healthcare service and patient outcomes at the two pre-existing hospitals did not improve. These outcomes included ambulance offload time: (Hospital A PRE: 10 min, POST: 10 min, P < 0.001; Hospital B PRE: 10 min, POST: 15 min, P < 0.001); ED length of stay: (Hospital A PRE: 242 min, POST: 246 min, P < 0.001; Hospital B PRE: 182 min, POST: 210 min, P < 0.001); and access block: (Hospital A PRE: 41%, POST: 46%, P < 0.001; Hospital B PRE: 23%, POST: 40%, P < 0.001). Time series modelling indicated that the effect was worst at the hospital furthest away from the new ED. CONCLUSIONS An additional ED within the region saw an increase in the total volume of presentations at a rate far greater than local population growth, suggesting it either provided an unmet need or a shifting of activity from one sector to another. Future studies should examine patient decision making regarding reasons for presenting to a new or pre-existing ED. There is an inherent need to take a 'whole of health service area' approach to solve crowding issues.
Collapse
Affiliation(s)
- J Crilly
- Gold Coast Hospital and Health Service, Southport, Australia; Griffith Health Institute, Griffith University, Gold Coast, Australia; State Wide Emergency Department Network, Brisbane, Australia
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Taylor K, Vandersluis H, Britton P, Wallis M. 4.1: Nonbiopsy of presumed fibroadenomas in patients <30 years: is it safe? A single unit experience and review of European practice. Breast Cancer Res 2013; 15 Suppl 1:O1-P53. [PMID: 24624992 PMCID: PMC3980303 DOI: 10.1186/bcr3498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
22
|
Duffy SW, Mackay J, Thomas S, Anderson E, Chen THH, Ellis I, Evans G, Fielder H, Fox R, Gui G, Macmillan D, Moss S, Rogers C, Sibbering M, Wallis M, Warren R, Watson E, Whynes D, Allgood P, Caunt J. Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study. Health Technol Assess 2013; 17:vii-xiv, 1-95. [PMID: 23489892 DOI: 10.3310/hta17110] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Women with a significant family history of breast cancer are often offered more intensive and earlier surveillance than is offered to the general population in the National Breast Screening Programme. Up to now, this strategy has not been fully evaluated. OBJECTIVE To evaluate the benefit of mammographic surveillance for women aged 40-49 years at moderate risk of breast cancer due to family history. The study is referred to as FH01. DESIGN This was a single-arm cohort study with recruitment taking place between January 2003 and February 2007. Recruits were women aged < 50 years with a family history of breast or ovarian cancer conferring at least a 3% risk of breast cancer between ages 40 and 49 years. The women were offered annual mammography for at least 5 years and observed for the occurrence of breast cancer during the surveillance period. The age group 40-44 years was targeted so that they would still be aged < 50 years after 5 years of surveillance. SETTING Seventy-four surveillance centres in England, Wales, Scotland and Northern Ireland. PARTICIPANTS A total of 6710 women, 94% of whom were aged < 45 years at recruitment, with a family history of breast cancer estimated to imply at least a 3% risk of the disease between the ages of 40 and 50 years. INTERVENTIONS Annual mammography for at least 5 years. MAIN OUTCOME MEASURES The primary study end point was the predicted risk of death from breast cancer as estimated from the size, lymph node status and grade of the tumours diagnosed. This was compared with the control group from the UK Breast Screening Age Trial (Age Trial), adjusting for the different underlying incidence in the two populations. RESULTS As of December 2010, there were 165 breast cancers diagnosed in 37,025 person-years of observation and 30,556 mammographic screening episodes. Of these, 122 (74%) were diagnosed at screening. The cancers included 44 (27%) cases of ductal carcinoma in situ. There were 19 predicted deaths in 37,025 person-years in FH01, with an estimated incidence of 6.3 per 1000 per year. The corresponding figures for the Age Trial control group were 204 predicted deaths in 622,127 person-years and an incidence of 2.4 per 1000 per year. This gave an estimated 40% reduction in breast cancer mortality (relative risk = 0.60; 95% confidence interval 0.37 to 0.98; p = 0.04). CONCLUSIONS Annual mammography in women aged 40-49 years with a significant family history of breast or ovarian cancer is both clinically effective in reducing breast cancer mortality and cost-effective. There is a need to further standardise familial risk assessment, to research the impact of digital mammography and to clarify the role of breast density in this population. TRIAL REGISTRATION National Research Register N0484114809. FUNDING This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 17, No. 11. See the HTA programme website for further project information.
Collapse
Affiliation(s)
- S W Duffy
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Rajan S, Foreman J, Wallis MG, Caldas C, Britton P. Multidisciplinary decisions in breast cancer: does the patient receive what the team has recommended? Br J Cancer 2013; 108:2442-7. [PMID: 23736032 PMCID: PMC3694248 DOI: 10.1038/bjc.2013.267] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2013] [Revised: 05/08/2013] [Accepted: 05/12/2013] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND A multidisciplinary team (MDT) approach to breast cancer management is the gold standard. The aim is to evaluate MDT decision making in a modern breast unit. METHODS All referrals to the breast MDT where breast cancer was diagnosed from 1 July 2009 to 30 June 2011 were included. Multidisciplinary team decisions were compared with subsequent patient management and classified as concordant or discordant. RESULTS Over the study period, there were 3230 MDT decisions relating to 705 patients. Overall, 91.5% (2956 out of 3230) of decisions were concordant, 4.5% (146 out of 3230), were discordant and 4% (128 out of 3230) had no MDT decision. Of 146 discordant decisions, 26 (17.8%) were considered 'unjustifiable' as there was no additional information available after the MDT to account for the change in management. The remaining 120 discordant MDT decisions were considered 'justifiable', as management was altered due to patient choice (n=61), additional information available after MDT (n=54) or MDT error (n=5). CONCLUSION The vast majority of MDT decisions are implemented. Management alteration was most often due to patient choice or additional information available after the MDT. A minority of management alterations were 'unjustifiable' and the authors recommend that any patient whose treatment is subsequently changed should have MDT rediscussion prior to treatment.
Collapse
Affiliation(s)
- S Rajan
- Cambridge Breast Unit, Box 97, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
| | | | | | | | | |
Collapse
|
24
|
Taylor-Phillips S, Clarke A, Wheaton M, Kearins O, Wallis M. Fatigue and performance in interpreting breast screening mammograms. Breast Cancer Res 2012. [PMCID: PMC3542668 DOI: 10.1186/bcr3279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
25
|
Dawson S, Tsui D, Murtaza M, Biggs H, Chin S, Gale D, Forshew T, Wallis M, Rosenfeld N, Caldas C. Monitoring of Metastatic Breast Cancer Using Circulating Tumour DNA: A Comparison With Circulating Tumour Cells. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32772-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
26
|
Haill CF, Newell P, Ford C, Whitley M, Cox J, Wallis M, Best R, Jenks PJ. Compartmentalization of wards to cohort symptomatic patients at the beginning and end of norovirus outbreaks. J Hosp Infect 2012; 82:30-5. [PMID: 22770470 DOI: 10.1016/j.jhin.2012.05.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2012] [Accepted: 05/26/2012] [Indexed: 10/28/2022]
Abstract
BACKGROUND Outbreaks of norovirus can have a significant operational and financial impact on healthcare establishments. AIM To assess whether containment of symptomatic patients in single rooms and bays at the beginning and end of norovirus outbreaks reduced the length of bed closure. METHODS In 2007, we introduced a new strategy to limit the operational impact of hospital outbreaks of norovirus. Early in an outbreak, symptomatic patients were cohorted in single rooms or bays in an attempt to contain the outbreak without closing the entire ward. Once a ward had been closed, and as beds became available through discharges, patients were decanted into single rooms or empty bays with doors to facilitate earlier cleaning and opening of affected areas on the same ward. The impact of these changes was assessed by comparing outbreak data for two periods before and after implementation of the new strategy. FINDINGS Prior to June 2007, 90% of outbreaks were managed by closure of an entire ward, compared with only 54% from June 2007 onwards. The duration of closure was significantly shorter for bays compared with entire wards, both before (3.5 vs 6, P = 0.0327) and after (3 vs 5, P < 0.0001) June 2007. When considering all outbreaks, there was a significant reduction in duration of closure after the change in strategy (6 vs 5, P = 0.007). CONCLUSION Using ward compartmentalization to cohort affected patients at the beginning and end of norovirus outbreaks improved the efficiency of outbreak management and reduced operational disruption.
Collapse
Affiliation(s)
- C F Haill
- Department of Microbiology and Infection Prevention and Control, Derriford Hospital, Plymouth, UK
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Dawson S, Tsui D, Murtaza M, Biggs H, Chin S, Gale D, Forshew T, Wallis M, Caldas C, Rosenfeld N. 876 Non-invasive Monitoring of Metastatic Breast Cancer by Circulating Tumour DNA – a Comparison With Circulating Tumour Cells. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71508-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Rickard C, Webster J, Wallis M, Marsh N, McGrail M, French V, Foster L, Gallagher P, Gowardman J, McClymont A, Whitby M. Peripheral intravenous catheters can be left in situ until clinically indicated for removal: Randomised controlled trial. Aust Crit Care 2012. [DOI: 10.1016/j.aucc.2011.12.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
29
|
Wallis MG, Clements K, Kearins O, Ball G, Macartney J, Lawrence GM. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 2012; 106:1611-7. [PMID: 22516949 PMCID: PMC3349181 DOI: 10.1038/bjc.2012.151] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND The incidence of ductal carcinoma in situ (DCIS) rose rapidly when the NHS Breast Screening Programme (NHSBSP) started in 1988. Some authorities consider that this represents both over-diagnosis and over-treatment. We report long-term follow-up of DCIS diagnosed in the first 10 years (April 1988 to March 1999) of the West Midlands NHSBSP. METHODS 840 noninvasive breast cancers were recorded on the national breast screening computer system. Following exclusions, and thorough case note and pathology review, 700 DCIS cases were identified for follow-up. RESULTS After a median follow-up of 183 (range 133 to 259) months, 102 (14.6%) first local recurrences were identified, 49 (48%) were invasive. Median time to first noninvasive recurrence was 15 months, and 60 months for invasive recurrence. Median time to invasive recurrence was 76 months from initially high-grade DCIS, and 131 months from low/intermediate grade DCIS. For the seven women, presenting with metastasis as their first event, the median time was 82 (range 15 to 188) months. The cumulative proportion developing recurrence at 180 months was twice as high as at 60 months. INTERPRETATION Short-term follow-up of patients diagnosed with DCIS will miss significant numbers of events, especially invasive local recurrences.
Collapse
Affiliation(s)
- M G Wallis
- Cambridge Breast Unit and NIHR Cambridge Biomedical Research Unit, Box 97, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.
| | | | | | | | | | | |
Collapse
|
30
|
Taylor K, Britton PD, O'Keeffe S, Wallis MG. Quantification of the UK five-point breast imaging classification and mapping to BI-RADS: to facilitate comparison of reporting, research and published literature. Breast Cancer Res 2011. [PMCID: PMC3238271 DOI: 10.1186/bcr2986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
31
|
Warren LM, Mackenzie A, Cooke J, Given-Wilson R, Wallis M, Chakraborty D, Dance DR, Young KC. Dependence of detectability of microcalcification clusters on quality of mammography images. Breast Cancer Res 2011. [PMCID: PMC3238260 DOI: 10.1186/bcr2975] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
32
|
Taylor K, Britton P, O'Keeffe S, Wallis MG. Quantification of the UK 5-point breast imaging classification and mapping to BI-RADS to facilitate comparison with international literature. Br J Radiol 2011; 84:1005-10. [PMID: 22011830 PMCID: PMC3473699 DOI: 10.1259/bjr/48490964] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2010] [Revised: 01/07/2011] [Accepted: 01/20/2011] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE The UK 5-point breast imaging scoring system, recently formalised by the Royal College of Radiologists Breast Group, does not specify the likelihood of malignancy in each category. The breast imaging and reporting data system (BI-RADS) is widely used throughout North America and much of Europe. The main purpose of this study is to quantify the cancer likelihood of each of the UK 5-point categories and map them to comparable BI-RADS categories to facilitate comparison with North American and European literature and publication of UK research abroad. METHODS During the 8 year study period, mammogram and ultrasound results were UK scored and the percentage of cancer outcomes within each group calculated. These were then compared with the percentage incidence of the BI-RADS categories. RESULTS Of 23 741 separate assessment episodes, 15 288 mammograms and 10 642 ultrasound examinations were evaluated. There was a direct correlation between UK scoring and BI-RADS for categories 1 and 5. UK Score 2 lipomas and simple cysts correlated with BI-RADS 2, with the remaining UK Score 2 lesions (mostly fibroadenomas) assigned to BI-RADS 3. BI-RADS 4 incorporates a wide range of cancer risk (2-95%) with subdivisions a, b and c indicating increasing, but unspecified, likelihood of malignancy. UK Score 3 correlated with BI-RADS 4 a/b and UK Score 4 corresponded with BI-RADS 4c. CONCLUSION This study quantifies the cancer likelihood of the UK scoring and maps them to parallel BI-RADS categories, with equivalent cancer risks. This facilitates the ability to share UK research data and clinical practice on an international scale.
Collapse
Affiliation(s)
- K Taylor
- Department of Radiology, Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
| | | | | | | |
Collapse
|
33
|
Taylor-Phillips S, Clarke A, Wheaton M, Wallis M, Duncan A, Gale A. Does the performance of mammography readers in the NHSBSP vary? And how much does this matter? Br J Soc Med 2011. [DOI: 10.1136/jech.2011.143586.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Taylor K, O'Keeffe S, Britton PD, Wallis MG, Treece GM, Housden J, Parashar D, Bond S, Sinnatamby R. Ultrasound elastography as an adjuvant to conventional ultrasound in the preoperative assessment of axillary lymph nodes in suspected breast cancer: a pilot study. Clin Radiol 2011; 66:1064-71. [PMID: 21835398 DOI: 10.1016/j.crad.2011.05.015] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2011] [Revised: 04/27/2011] [Accepted: 05/13/2011] [Indexed: 12/21/2022]
Abstract
AIMS To compare the performance of ultrasound elastography with conventional ultrasound in the assessment of axillary lymph nodes in suspected breast cancer and whether ultrasound elastography as an adjunct to conventional ultrasound can increase the sensitivity of conventional ultrasound used alone. MATERIALS AND METHODS Fifty symptomatic women with a sonographic suspicion for breast cancer underwent ultrasound elastography of the ipsilateral axilla concurrent with conventional ultrasound being performed as part of triple assessment. Elastograms were visually scored, strain measurements calculated and node area and perimeter measurements taken. Theoretical biopsy cut points were selected. The sensitivity, specificity, positive predictive value (PPV), and negative predictive values (NPV) were calculated and receiver operating characteristic (ROC) analysis was performed and compared for elastograms and conventional ultrasound images with surgical histology as the reference standard. RESULTS The mean age of the women was 57 years. Twenty-nine out of 50 of the nodes were histologically negative on surgical histology and 21 were positive. The sensitivity, specificity, PPV, and NPV for conventional ultrasound were 76, 78, 70, and 81%, respectively; 90, 86, 83, and 93%, respectively, for visual ultrasound elastography; and for strain scoring, 100, 48, 58 and 100%, respectively. There was no significant difference between any of the node measurements CONCLUSIONS Initial experience with ultrasound elastography of axillary lymph nodes, showed that it is more sensitive than conventional ultrasound in detecting abnormal nodes in the axilla in cases of suspected breast cancer. The specificity remained acceptable and ultrasound elastography used as an adjunct to conventional ultrasound has the potential to improve the performance of conventional ultrasound alone.
Collapse
Affiliation(s)
- K Taylor
- Department of Radiology, Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Wallis M. John Harold Wallis. West J Med 2011. [DOI: 10.1136/bmj.d3876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Allgood PC, Duffy SW, Kearins O, O'Sullivan E, Tappenden N, Wallis MG, Lawrence G. Explaining the difference in prognosis between screen-detected and symptomatic breast cancers. Br J Cancer 2011; 104:1680-5. [PMID: 21540862 PMCID: PMC3111158 DOI: 10.1038/bjc.2011.144] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 03/24/2011] [Accepted: 03/29/2011] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND We analysed 10-year survival data in 19,411 women aged 50-64 years diagnosed with invasive breast cancer in the West Midlands region of the United Kingdom. The aim was to estimate the survival advantage seen in cases that were screen detected compared with those diagnosed symptomatically and attribute this to shifts in prognostic variables or survival differences specific to prognostic categories. METHODS We studied tumour size, histological grade and the Nottingham Prognostic Index in very narrow categories and investigated the distribution of these prognostic factors within screen-detected and symptomatic tumours. We also adjusted for lead time bias. RESULTS The unadjusted 10-year breast cancer survival in screen-detected cases was 85.5% and in symptomatic cases 62.8%; after adjustment for lead time bias, survival in the screen-detected cases was 79.3%. Within narrow categories of prognostic variables, survival differences were small, indicating that the majority of the survival advantage of screen detection is due to differences in the distributions of size and node status. CONCLUSION Our results suggested that a combination of lead time with size and node status in 10 categories explained almost all (97%) of the survival advantage. Only a small proportion remained to be explained by biological differences, manifested as length bias or overdiagnosis.
Collapse
Affiliation(s)
- P C Allgood
- CR-UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute for Preventive Medicine, Charterhouse Square, London WC1M 6BQ, UK.
| | | | | | | | | | | | | |
Collapse
|
37
|
Britton P, Warwick J, Wallis MG, O'Keeffe S, Taylor K, Sinnatamby R, Barter S, Gaskarth M, Duffy SW, Wishart GC. Measuring the accuracy of diagnostic imaging in symptomatic breast patients: team and individual performance. Br J Radiol 2011; 85:415-22. [PMID: 21224304 DOI: 10.1259/bjr/32906819] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE The combination of mammography and/or ultrasound remains the mainstay in current breast cancer diagnosis. The aims of this study were to evaluate the reliability of standard breast imaging and individual radiologist performance and to explore ways that this can be improved. METHODS A total of 16,603 separate assessment episodes were undertaken on 13,958 patients referred to a specialist symptomatic breast clinic over a 6 year period. Each mammogram and ultrasound was reported prospectively using a five-point reporting scale and compared with final outcome. RESULTS Mammographic sensitivity, specificity and receiver operating curve (ROC) area were 66.6%, 99.7% and 0.83, respectively. The sensitivity of mammography improved dramatically from 47.6 to 86.7% with increasing age. Overall ultrasound sensitivity, specificity and ROC area was 82.0%, 99.3% and 0.91, respectively. The sensitivity of ultrasound also improved dramatically with increasing age from 66.7 to 97.1%. Breast density also had a profound effect on imaging performance, with mammographic sensitivity falling from 90.1 to 45.9% and ultrasound sensitivity reducing from 95.2 to 72.0% with increasing breast density. CONCLUSION The sensitivity ranges widely between radiologists (53.1-74.1% for mammography and 67.1-87.0% for ultrasound). Reporting sensitivity was strongly correlated with radiologist experience. Those radiologists with less experience (and lower sensitivity) were relatively more likely to report a cancer as indeterminate/uncertain. To improve radiology reporting performance, the sensitivity of cancer reporting should be closely monitored; there should be regular feedback from needle biopsy results and discussion of reporting classification with colleagues.
Collapse
Affiliation(s)
- P Britton
- Department of Radiology, Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Taylor K, O’Keeffe S, Treece GM, Sinnatamby R, Britton PD, Wallis MG. Ultrasound elastography as an adjuvant to conventional ultrasound in the preoperative assessment of axillary lymph nodes in suspected breast cancer: a pilot study. Breast Cancer Res 2010. [PMCID: PMC2978813 DOI: 10.1186/bcr2649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
|
39
|
Gounaris I, Sinnatamby R, Taylor K, Wallis M, Hiller L, Vallier AL, Provenzano E, Iddawela M, Wishart G, Earl H, Britton P. O-31 Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patient. EJC Suppl 2010. [DOI: 10.1016/j.ejcsup.2010.06.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
40
|
Abstract
1. A method is described for the chromatographic preparation of ox growth hormone. It involves chromatography of an extract of anterior pituitary lobes on DEAE-cellulose, followed by rechromatography on a dextran gel of low cross-linkage (Sephadex G-100). 2. The product is highly active in growth-hormone assays, and is obtained in good yield. It was homogeneous by several criteria, but showed some heterogeneity on starch-gel electrophoresis. 3. The molecular weight of the hormone was estimated from its behaviour on gel-filtration columns under various conditions. Evidence that the hormone may dissociate into sub-units under some conditions is presented.
Collapse
Affiliation(s)
- M Wallis
- Department of Biochemistry, University of Cambridge
| | | |
Collapse
|
41
|
Abstract
Human preprothyrotrophin-releasing hormone (ppTRH) includes six copies of the TRH sequence, the rat and mouse precursors have five, and those of non-mammalian vertebrates have up to eight. In the present study, the evolutionary basis of this variation was investigated using ppTRH gene sequences extracted from available vertebrate genomic databases. A structure based on eight TRH repeats appears to be the norm for non-mammalian vertebrates, but in all mammals except monotremes this number is reduced to a maximum of six. In some species, one (or more) of the TRH repeats has been mutated, probably rendering it functionless and, in a few species, one or two copies of the TRH sequence have been deleted completely. Sequences of regions between the TRH sequences are poorly conserved, despite reports that several active peptides are produced from these regions. The 5' untranslated region of ppTRH is also very variable but, in eutherians, the promoter region immediately upstream of the gene is quite strongly conserved. In particular, those sequences identified as being involved in transcriptional regulation are well conserved in most eutherians, although they are largely absent from other vertebrates. In most species, gene order around the ppTRH locus is conserved, although exceptions include man and chimpanzee, as well as rat and mouse. The comparative genomics approach thus provides a wider view than previously available of the range of ppTRH genes in vertebrates, and of the species specificity displayed by this molecule.
Collapse
Affiliation(s)
- M Wallis
- Biochemistry Department, School of Life Sciences, University of Sussex, Brighton, UK.
| |
Collapse
|
42
|
Britton P, Moyle P, Benson J, Goud A, Sinnatamby R, Barter S, Gaskarth M, Provenzano E, Wallis M. Ultrasound of the axilla: where to look for the sentinel lymph node. Clin Radiol 2010; 65:373-6. [DOI: 10.1016/j.crad.2010.01.013] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2009] [Revised: 01/05/2010] [Accepted: 01/08/2010] [Indexed: 12/01/2022]
|
43
|
Lin F, Chaboyer W, Wallis M. The influence of individual power and interdepartmental mistrust on the ICU patient discharge process. Aust Crit Care 2010. [DOI: 10.1016/j.aucc.2009.12.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
44
|
Baskaran V, Bali R, Arochena H, Naguib R, Wheaton M, Wallis M, Benson T, Wickramasinghe N. Physician intervention via knowledge management: using HL7 messaging to increase breast-screening uptake. IJBET 2010. [DOI: 10.1504/ijbet.2010.034944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
45
|
Taylor K, Britton P, Sonoda L, Wallis M, Sinnatamby R. Is it safe practice not to biopsy fibroadenomas in women under 30? Breast Cancer Res 2009. [PMCID: PMC4284832 DOI: 10.1186/bcr2371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
46
|
Britton P, Duffy SW, Sinnatamby R, Wallis MG, Barter S, Gaskarth M, O'Neill A, Caldas C, Brenton JD, Forouhi P, Wishart GC. One-stop diagnostic breast clinics: how often are breast cancers missed? Br J Cancer 2009; 100:1873-8. [PMID: 19455145 PMCID: PMC2714235 DOI: 10.1038/sj.bjc.6605082] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
The aim of this study was to estimate the number of patients discharged from a symptomatic breast clinic who subsequently develop breast cancer and to determine how many of these cancers had been ‘missed’ at initial assessment. Over a 3-year period, 7004 patients were discharged with a nonmalignant diagnosis. Twenty-nine patients were subsequently diagnosed with breast cancer over the next 36 months. This equates to a symptomatic ‘interval’ cancer rate of 4.1 per 1000 women in the 36 months after initial assessment (0.9 per 1000 women within 12 months, 2.6 per 1000 women within 24 months). The lowest sensitivity of initial assessment was seen in patients of 40–49 years of age, and these patients present the greatest imaging and diagnostic challenge. Following multidisciplinary review, a consensus was reached on whether a cancer had been missed or not. No delay occurred in 10 patients (35%) and probably no delay in 7 patients (24%). Possible delay occurred in three patients (10%) and definite delay in diagnosis (i.e., a ‘missed’ cancer) occurred in only nine patients (31%). The overall diagnostic accuracy of ‘triple’ assessment is 99.6% and the ‘missed’ cancer rate is 1.7 per 1000 women discharged.
Collapse
Affiliation(s)
- P Britton
- Department of Radiology, Cambridge Breast Unit, Box 97, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Britton P, Provenzano E, Barter S, Gaskarth M, Goud A, Moyle P, Sinnatamby R, Wallis M, Benson J, Forouhi P, Wishart G. Ultrasound guided percutaneous axillary lymph node core biopsy: How often is the sentinel lymph node being biopsied? Breast 2009; 18:13-6. [DOI: 10.1016/j.breast.2008.09.003] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2008] [Revised: 09/03/2008] [Accepted: 09/10/2008] [Indexed: 10/21/2022] Open
|
48
|
Britton PD, Forouhi P, O'Neill A, Wallis M, Sinnatamby R, Gaskarth M, Sue B, John BR, Wishart GC. The sensitivity of multidisciplinary triple assessment for diagnosing breast cancer in a symptomatic breast clinic. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-6009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #6009
Introduction: Triple assessment by a multidisciplinary team comprising clinical and radiological examination, supplemented with tissue diagnosis is the standard of care for evaluating patients with potential breast cancer in symptomatic breast clinics in the U.K. Currently there are no guidelines for acceptable sensitivity of this process. This study reports the proportion of patients who return with breast cancer after initially having been reassured and discharged (analogues to screening “interval” cancer)
 Methods: All new symptomatic episodes in the 3 year period from 01/01/2001 to 31/12/2003 were identified using a dedicated database. Patients discharged with a non-cancer diagnosis were traced through the database for a further 3 years and the clinical and imaging records of those subsequently diagnosed with cancer reviewed. Tissue diagnosis was obtained using percutaneous core biopsy in all cases.
 Results: Of the 7,740 new symptomatic patients assessed 518 (6.7%) were diagnosed with breast cancer and 7222 were discharged. Of these, 32 patients were diagnosed with breast cancer over the next 3 years (5 within 12 months, 19 within 24months). This equates to a symptomatic “interval” cancer rate of 0.6 per thousand women within 12 months, 2.5 per thousand women within 24 months and 4.1 per thousand women within 36 months. This reflects an overall sensitivity for histology-based triple assessment of 99.6%. On review a definite delay in diagnosis was found in 5 (16%, 0.6/1000), a possible delay in 9 (28%, 1.1/1000) and no delay in diagnosis (no signs of disease on original radiology and no related clinical findings) in 18 (56%).
 Conclusion: In this series less than 2 per thousand women discharged from a symptomatic clinic were subsequently found to have a cancer that might have been diagnosed at initial assessment, with an overall sensitivity for triple assessment of 99.6%. Modern multi-disciplinary “triple” assessment is a safe method of evaluating patients with potential breast cancer.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6009.
Collapse
Affiliation(s)
- PD Britton
- 1 Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
| | - P Forouhi
- 1 Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
| | - A O'Neill
- 1 Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
| | - M Wallis
- 1 Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
| | - R Sinnatamby
- 1 Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
| | - M Gaskarth
- 1 Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
| | - B Sue
- 1 Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
| | - BR John
- 1 Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
| | - GC Wishart
- 1 Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
| |
Collapse
|
49
|
Baskaran V, Bali R, Arochena H, Naguib R, Wheaton M, Wallis M, Wickramasinghe N. A knowledge-based primary care approach to increase breast screening attendance. IJBET 2009. [DOI: 10.1504/ijbet.2009.022914] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
50
|
Robertson W, Friede T, Blissett J, Rudolf MCJ, Wallis M, Stewart-Brown S. Pilot of "Families for Health": community-based family intervention for obesity. Arch Dis Child 2008; 93:921-6. [PMID: 18463121 DOI: 10.1136/adc.2008.139162] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To develop and evaluate "Families for Health", a new community based family intervention for childhood obesity. DESIGN Programme development, pilot study and evaluation using intention-to-treat analysis. SETTING Coventry, England. PARTICIPANTS 27 overweight or obese children aged 7-13 years (18 girls, 9 boys) and their parents, from 21 families. INTERVENTION Families for Health is a 12-week programme with parallel groups for parents and children, addressing parenting, lifestyle change and social and emotional development. MAIN OUTCOME MEASURES Change in baseline BMI z score at the end of the programme (3 months) and 9-month follow-up. Attendance, drop-out, parents' perception of the programme, child's quality of life and self-esteem, parental mental health, parent-child relationships and lifestyle changes were also measured. RESULTS Attendance rate was 62%, with 18 of the 27 (67%) children completing the programme. For the 22 children with follow-up data (including four who dropped out), BMI z score was reduced by -0.18 (95% CI -0.30 to -0.05) at 3 months and -0.21 (-0.35 to -0.07) at 9 months. Statistically significant improvements were observed in children's quality of life and lifestyle (reduced sedentary behaviour, increased steps and reduced exposure to unhealthy foods), child-parent relationships and parents' mental health. Fruit and vegetable consumption, participation in moderate/vigorous exercise and children's self-esteem did not change significantly. Topics on parenting skills, activity and food were rated as helpful and used with confidence by most parents. CONCLUSIONS Families for Health is a promising new childhood obesity intervention. Definitive evaluation of its clinical effectiveness by randomised controlled trial is now required.
Collapse
Affiliation(s)
- W Robertson
- Health Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, UK.
| | | | | | | | | | | |
Collapse
|